NCT06522386 2026-04-16
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
164 trialsNCT01661881 2026-04-08
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05976763 2026-04-07
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT03623373 2026-03-30
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT02682641 2026-03-27
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Active not recruiting
NCT02446236 2026-03-24
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
Phase 1 Active not recruiting
NCT01479842 2026-03-23
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05025800 2026-03-20
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06263491 2026-03-20
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03523975 2026-03-13
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Recruiting
NCT06572618 2026-03-13
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT05495464 2026-02-27
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT01880567 2026-02-19
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02858804 2026-02-11
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT03710772 2026-02-11
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07285590 2025-12-16
IMCL-2023
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT07272499 2025-12-09
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
Phase 2 Recruiting
NCT02427620 2025-11-21
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06839053 2025-11-19
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04765111 2025-11-10
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07199296 2025-09-30
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
Phase 2 Recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT03834688 2025-08-11
PrE0405
PrECOG, LLC.
Phase 2 Completed
NCT00878254 2025-07-23
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
University of Miami
Phase 2 Completed
NCT05025423 2025-06-13
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03863184 2025-06-06
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06846489 2025-06-03
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Sun Yat-sen University
Phase 2 Recruiting
NCT03295240 2025-05-13
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT01318317 2025-04-25
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04047797 2025-04-20
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05635162 2025-04-16
ZEBRA
University College, London
Phase 2 Recruiting
NCT05004064 2025-04-09
CARAMEL
University College, London
Phase 2 Recruiting
NCT03440567 2025-03-26
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT01865110 2025-03-05
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT04624958 2024-10-18
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
Sun Yat-sen University
Phase 2 Active not recruiting
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT04659044 2024-09-19
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Terminated
NCT00877214 2024-08-22
MAINTAIN
University of Giessen
Phase 3 Active not recruiting
NCT01456351 2024-08-22
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
University of Giessen
Phase 3 Completed
NCT01472562 2024-07-16
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT06496308 2024-07-11
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Ruijin Hospital
Phase 3 Recruiting
NCT05868395 2024-05-29
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Medical University of Vienna
Phase 2 Recruiting
NCT00863369 2024-03-20
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1/2 Completed
NCT04626791 2024-03-12
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT00577278 2024-02-16
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
Phase 2 Completed
NCT00007865 2023-12-27
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed